DaVita (DVA) Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Adjusted Operating Income: $482 million, exceeding forecasts by approximately $50 million.

Adjusted EPS: $2.87, with guidance raised to $14.10 - $15.20 per share for the year.

Free Cash Flow: $140 million, guidance remains unchanged due to variability.

Treatment Volume: Slightly above forecast; full-year growth expectations raised from flat to 25-50 basis points.

Revenue per Treatment (RPT): Declined by $5 sequentially but showed a year-over-year growth of approximately 4%. Full-year growth expected at 1-2%.

Patient Care Cost per Treatment: Flat compared to Q4, with lower-than-expected costs due to productivity improvements.

2Strategic Updates and Business Highlights

Integrated Kidney Care (IKC): Continued momentum with improvements in CMS metrics, achieving the highest aggregate savings in the CKCC program.

Technology Investments: Focus on enhancing IT systems and deploying AI solutions to improve operational efficiency and clinical outcomes.

Market Positioning: Actively capturing market share from competitors, particularly due to clinic closures by Fresenius, with expectations for patient transfers to contribute positively to treatment growth.

3Forward Guidance and Outlook

Adjusted Operating Income Guidance: Raised to $2.15 billion - $2.25 billion, primarily driven by higher treatment volume and lower patient care costs.

Volume Growth Expectations: Increased to 25-50 basis points for the year, with expectations for treatment per normalized day growth to reach 50-75 basis points.

RPT Guidance: Maintained at 1-2% growth for the year, despite Q1's strong performance.

4Bad News, Challenges, or Points of Concern

ACA Impact: Although ACA enrollment is trending better than expected, the mix of patients selecting lower-level plans could lead to higher out-of-pocket costs and a modest RPT headwind.

Competitive Pressures: Ongoing clinic closures by competitors may impact patient retention and market dynamics.

G&A Costs: Increased by 13% year-over-year due to technology investments, raising concerns about cost management relative to revenue growth.

5Notable Q&A Insights

Volume Dynamics: Weather and flu season impacts were in line with forecasts, with better-than-expected mortality contributing to volume growth.

RPT Variability: The strong RPT in Q1 was partly due to timing effects; however, the company expects to maintain its annual guidance despite fluctuations.

Market Share Capture: DaVita is focused on leveraging clinic closures by competitors to attract new patients, although the extent of this impact remains uncertain.

Technology Investments: Long-term benefits are anticipated from technology initiatives, though the immediate impact on operating performance is still being assessed. Overall, DaVita reported a strong start to 2026 with improved financial metrics and strategic initiatives aimed at enhancing clinical outcomes and operational efficiency, while navigating challenges related to market competition and ACA impacts.